The chemical class termed SSU72 Inhibitors encompasses a diverse group of compounds, primarily targeting pathways and processes related to RNA polymerase II transcription and pre-mRNA processing. This indirect approach is necessary due to the lack of direct inhibitors for SSU72. The key characteristic of these inhibitors is their ability to influence cellular mechanisms upstream or parallel to SSU72's function. The first group within this class comprises cyclin-dependent kinase (CDK) inhibitors like Flavopiridol Hydrochloride and Roscovitine. These compounds are crucial for their role in regulating transcription, a process closely associated with SSU72's activity. By inhibiting CDKs, these chemicals can potentially alter the phosphorylation state of RNA polymerase II, indirectly affecting SSU72's phosphatase activity. The alteration in the transcriptional landscape can have a downstream impact on SSU72's role in RNA processing. Another significant subset includes compounds like DRB, Triptolide, and α-Amanitin, known for their direct inhibition of RNA polymerase II. By blocking the transcriptional machinery, these inhibitors can indirectly modulate the substrates and functions associated with SSU72.
Additionally, chemicals like Actinomycin D, which intercalates into DNA and inhibits RNA synthesis, also fall under this category, offering a broader mechanism to affect SSU72's functional context. Furthermore, kinase inhibitors like Sorafenib, Sunitinib, Free Base, PD 98059, LY 294002, and Rapamycin, although primarily targeting other pathways like receptor tyrosine kinases, MAPK, PI3K, and mTOR pathways, respectively, can indirectly impact SSU72. These inhibitors affect a wide range of cellular signaling processes, potentially influencing the regulatory networks in which SSU72 operates. In summary, SSU72 inhibitors, though not directly targeting the phosphatase, offer a strategic approach to modulate its activity by influencing related transcriptional and signaling pathways. This approach reflects a growing understanding of the interconnected nature of cellular processes, where altering one component can have cascading effects on related proteins and functions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Flavopiridol Hydrochloride | 131740-09-5 | sc-207687 | 10 mg | $317.00 | ||
A cyclin-dependent kinase (CDK) inhibitor that can indirectly affect SSU72 by influencing RNA polymerase II transcription. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Another CDK inhibitor, potentially impacting SSU72 activity through transcription regulation. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
Inhibits RNA polymerase II transcription, potentially altering SSU72 function. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Known to inhibit transcription, may indirectly affect SSU72-mediated processes. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Binds to DNA and inhibits RNA synthesis, indirectly impacting SSU72 functions. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
Specifically inhibits RNA polymerase II, which can indirectly influence SSU72 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
While primarily a kinase inhibitor, it might indirectly affect SSU72 through signaling pathways. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
A receptor tyrosine kinase inhibitor that could indirectly impact SSU72 through cellular signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK, which is part of the MAPK pathway, potentially affecting SSU72 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, could indirectly impact SSU72 through signaling alterations. | ||||||